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Introduction 
Type 1 diabetes is a disease characterized 
by the specific destruction of insulin 
producing pancreatic beta-cells by the  
 
 
immune system (Cernea et al., 2008; 
Lehuen et al., 2010; Buschard, 2011; Eizirik 
et al., 2009; Padgett et al., 2013). Several 
animal models have been developed to 
Abstract 
Mice injected with multiple low dose of streptozotocin (mld-SZ) or transferred with  
mononuclear splenocytes (MS) from mld-SZ  donors constitute animal models that allow the 
study of  autoimmune diabetes. Mld-SZ mice show a progressive beta-cell destruction iniciated 
during non-specific islet inflammation involving free radicals as nitric oxide (NO°).  
Pharmacological inhibitors of NO° synthase delay or prevent the outbreak of disease, but have 
deleterious side effects when administered in vivo. The aim of this study, was to clarify the role 
of NO° on the ability of MS from mld-SZ mice to impair insulin secretion. Also, we investigated 
the beneficial effects of using NO° synthase inhibitors in vitro on anti-beta cells agression. 
Methods: NO° was measured in cultured MS and islets of Langerhans  isolated from mice at 
days 4 to 16  after the first mld-SZ injection. MS were also cultured with an inhibitor of NO° 
production, L-NG-monomethyl-arginine (L-NMMA), and then: a) injected in syngeneic mice to 
evaluate their insulin secretion patterns or b) co-cultured with islet cells to estimate the 
capacity of MS to exert in vitro cellular immune aggression. Results: Cultured islets of 
Langerhans and MS from mld-SZ mice showed increases in NO° production (p>0.05).  MS from 
mld-SZ mice, obtained at days 4 to 9 and precultured with L-NMMA showed ameliorations in 
their deleterious effect on insulin secretion from transferred recipient mice and from co-
cultured islet cells (p<0.05). Conclusions: These results suggest that the inhibition of NO° 
production “in vitro” reduced the aggressive capacity of MS from mld-SZ mice avoiding, at least 
in part, beta cell damage and destruction. 
 
Keywords: free radicals, murine autoimmune diabetes, non-specific islet inflammation, insulin 
secretion. 
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study the islet physiopathology leading to 
autoimmune diabetes mellitus. One of 
these models is the multiple low dose of 
streptozotocin (mld-SZ) treated mouse   
that presents cellular and humoral immune 
reactions against beta cells, presumably, 
made antigenic by mld-SZ injections (Like 
et al., 1976; Per-Ola  et al., 2000;  Mabley et 
al., 2008) and shows a time course of 
histologic changes and progressive 
impairments in insulin secretion and lipid 
metabolism. The process includes an 
increment in apoptotic islet cells, followed 
by insulitis and microfocal islet cell death. 
Also, an increase of plasma free fatty acids 
is accompanied by a diminished activity of 
pyruvate dehydrogenase complex in 
skeletal muscle, suggesting a reduced 
glucose oxidation. These changes precede 
appearance of hyperglycemia and impaired 
insulin secretion (O´Brien et al., 1996; 
Pighin et al., 2005 and  Karabatas et al., 
2005). 
 
Another animal model consists of an 
adoptive transfer of  mononuclear 
splenocytes (MS) from mld-SZ diabetic 
donors (diab.MS) to healthy syngeneic 
recipients. In these mice, a diminished 
insulin secretion is present 15 days after 
the transfer procedure, and a preferential 
trapping of transferred diab.MS in islets of 
recipient mice was observed.  Diab.MS 
obtained as early as day 4, were able to 
impair insulin secretion in transferred 
normal syngeneic recipients (Buschard et 
al., 1977; Pastorale et al., 2002; Karabatas 
et al., 2000 and 2005).   
 
It has been reported that in mld-SZ treated 
mice, beta-cell destruction can be initiated 
during non-specific islet inflammation 
involving toxic mediators such as cytokines 
and highly reactive free radicals as oxygen 
species and nitric oxide (NO°), produced by 
macrophages and endothelial cells. The 
beta-cells are particularly weakly protected 
against the toxicity of free radicals having a 
great vulnerability and sensitivity to this 
reactive species. Also the endocrine beta-
cells become an important source of NO° 
production when NO° synthase is induced 
by IL-1 (Karabatas et al., 1996; Flodstrom 
et al., 1999; Rydgren et al., 2002; Mabley et 
al., 2004; Lenzen, 2008; Eizirik et al., 2009; 
Yasuda et al., 2009). By using 
pharmacological inhibitors of NO° 
synthase, it has been evidenced that 
several of the deleterious actions of 
cytokines on rodent islet function “in vitro” 
are mediated by NO° formation. Several 
reports have indicated that inhibition of 
free radicals production protect against 
mld-SZ-induced diabetes in mice, since in 
vivo studies have shown a delay or 
prevention of the outbreak of disease after 
treatment with NO° synthase blockers 
(Karabatas et al., 1996; Maksimovic-Ivanic 
et al., 2002; Rydgren et al., 2002; Yang et 
al., 2003; Mabley et al., 2004 and 2008;). 
However, the lack of specificity of NO° 
synthase pharmacological inhibitors, which 
to a varying degree block inducible and 
constitutive isoform of the enzyme, leads to 
uncontrolled side effects (blood pressure, 
neurotransmission, body weight) when 
administered in vivo. 
 
The aim of this study was to investigate the 
role of NO° on the ability of diab.MS to 
impair insulin secretion when injected in 
normal recipient mice or when co-cultured 
with dispersed islet cells. We studied nitric 
oxide production in cultured MS and islets 
of Langerhans, isolated from control or 
mld-SZ mice at 4, 6, 9, 12 and 16 days after 
the first injection. MS were also cultured 
with an inhibitor of nitric oxide production, 
L-NG-monomethyl-arginine (L-NMMA). 
After being properly washed, these cells 
were used to study:  
a) insulin secretion patterns in mice 
transferred with MS and  
b) the capacity of diab.MS to exert an in 
vitro anti beta-cell immune aggression 
when co-cultured with dispersed islet cells. 
 
Materials and Methods 
Animals 
 
Male C57BL/6J inbred mice weighing 21 to 
25 g were obtained from the Centro Nacional 
de Genetica Medica, Buenos Aires, Argentina. 
Three-month-old male Wistar rats were also 
used as source of islet cells for co-culture 
experiments. Animals were housed in rooms 
with controlled temperature (23°C) and a 
fixed 12-hour artificial light-dark cycle and 
had free access to water and to a standard 
laboratory chow (Carhill, Buenos Aires, 
Argentina). The protocols of animal use 
3                                                                                                                                                      JMED Research 
________________________________________________________ 
 
______________ 
 
Liliana Karabatas and Claudia Pastorale (2013), JMED Research, DOI: 10.5171/2013. 256606 
comply the guidelines recommended by the 
National Institutes of Health; and were 
approved by the Institutional Review 
Board  at Hospital de Niños R. Gutiérrez 
(#CODI-1811). 
 
 Mice Injected with Multiple Low-Dose 
Streptozotocin (mld-SZ) 
 
C57BL/6J mice were injected 
intraperitoneally with 0.1 ml citrate buffer 
(0.1 mol/l trisodium citrate, 0.1 mol/l citric 
acid, pH=4.5), or with 40 mg/kg body 
weight of streptozotocin (SIGMA,USA) 
dissolved in 0.1 ml citrate buffer, for five 
consecutive days. Animals were killed by 
cervical dislocation at days 4 (before the 
fourth injection), 6, 9, 12 or 16 after the 
first injection of SZ or buffer alone. Blood 
samples for determination of plasma 
glucose levels were obtained by 
retroorbital sinus puncture in 
unanesthetized, nonfasted mice 24 h before 
the beginning of mld-SZ or buffer injections 
and on day 4, 6, 9, 12 and 16 after the first 
injection. Pancreata and spleens were 
obtained from mice at the time of death.  
 
Islets of Langerhans were obtained from 
collagenase-treated (SIGMA,  USA) mice 
pancreas according to the method of Lacy 
and Kostianovsky (1967), and were 
perifused to evaluate glucose-induced 
insulin secretion, or cultured 22 h to 
evaluate NO° production as described 
below. 
 
Mononuclear splenocytes (MS) were 
aseptically isolated by shredding the 
spleens with steel wire mesh with sterile 
NaCl 154 mmol/l solution (Buschard et al., 
1977; Karabatas et al., 2000 and 2005). MS 
were obtained using a LymphoprepTM 
gradient (Nycomed Pharma, Norway) and 
then washed three times with sterile saline 
solution. Cell viability was assayed by the 
Trypan blue exclusion test (Phillips, 1973) 
and was 95 to 98%. Isolated MS were used 
to evaluate NO° production in 22 h cultures 
(see Nitrite production). MS were also 
cultured 22 hs without  or with 0.5 mM  L-
NG-monomethyl-arginine (L-NMMA, an 
inhibitor of nitric oxide synthase) and then 
transferred into syngeneic recipient mice 
or used to study “in vitro” cellular immune 
aggression (CIA). 
Nitrite Production in Cultured Islets and MS 
 
Islets of Langerhans and MS were obtained 
as described above from mice killed 4, 6, 9, 
12 or 16 days after the first injection of mld-
SZ or citrate buffer alone. Groups of 200 
islets were cultured for 22 h under an 
atmosphere of 95% air/5% CO2 in 400 µl of 
RPMI 1640 (without phenol red) 
supplemented with 60 mg/l streptomycin, 1 
mmol/l sodium pyruvate, 10 ml/l non-
essential amino acids 100X, 23.8 mmol/l  
NaHCO3, 10 mmol/l HEPES and 10% heat 
inactivated fetal calf serum (Gibco, UK). Also, 
107 MS were cultured 22 h in culture 
medium.  
 
Nitrite determination  was performed   with 
250 µl of supernatants of cultured  islets or 
MS  mixed with 250 µl of  Griess reagent and 
incubated for 10 minutes at room 
temperature. Nitrite was determined 
according to the method described by Green 
( 1982). For our experiment , the detection  
limit was 0.5 µM, corresponding to 0.8 
pmol/islet and 20 pmol/106 MS.  Intra- and  
interassay coefficients of variation on the 
standard curve were 1 µM: 5.5%, 9,4%; 5 
µM: 1.2%, 11.0%; 25 µM: 0.3%, 4.0%. 
Results are expressed as pmol of nitrite per 
islet or pmol of nitrite per 106 MS. 
 
In another set of experiments, MS were 
cultured 22 h with or without L-NMMA 0.5 
mM and nitrite was determined in 
supernatants. Nitrite levels of medium 
without MS (with or without L-NMMA) were 
subtracted if their values were above the 
detection limit.  
 
Transfer of MS from Mld-SZ Mice to Syngeneic 
Animals 
  
MS obtained from mld-SZ-mice (diab.MS) or 
from citrate buffer-injected mice (ctr.MS) at 
days 4, 6, 9, 12 or 16 after the first injection  
were washed twice with RPMI 1640 and 
cultured in this medium (5x107 MS/50 ml of 
culture medium) for 22 hs with or without 
0,5 mM L-NMMA. Afterward MS were 
washed twice with sterile saline solution. 
Viability of MS was then assesed by Trypan 
blue exclusion (Phillips, 1973)  and 5x107 
viable MS (90-95% viability), suspended in 
0.2 ml sterile NaCl 154 mmol/l solution) 
were injected ip in C57BL/6J male recipient 
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mice of 22-24 g. Fifteen days after the 
transfer procedure, recipient mice were 
killed by cervical dislocation and their 
pancreas were quickly removed and 
processed for isolated islet perifusion as 
described below. Blood samples from 
unanesthetized, non-fasted recipient mice 
were obtained by retroorbital sinus 
puncture before and 15 days after being 
transferred. All experiments were carried 
out between 10:00 and 12:00 AM. 
 
Perifusion of Pancreatic Islets 
 
Islets of Langerhans from mld-SZ mice or 
from mice transferred with MS were 
perifused (25-40 islets per chamber) as 
described previously (Karabatas et al., 2000 
and 2005).  Krebs-Ringer-bicarbonate buffer 
was utilized as the perifusion buffer, and was 
supplemented with 1% (w/v) dextran 70 
(Sigma, St. Louis, Missouri, USA) and 3.3 
mmol/l glucose. The pH of the buffer, kept 
under constant 95% O2, 5% CO2 gassing was 
7.38-7.40. Samples were collected, after an 
initial 15 min recuperation period, on 0.2 ml 
of 0.25 mol/l EDTA in tubes kept at 4°C and 
immediately frozen at -20°C. Samples from 
min 1 and 2 were used for baseline 
determinations. A stimulus of 16.5 mmol/l 
glucose was added to the perifusion buffer 
from min 3 to 40. Islets were perifused with 
buffer containing 3.3 mmol/l glucose from 
min 40 to 50. Perifusion flux was 0.8-1.1 
ml/min.  
 
"In Vitro" Cellular Immune Aggression (CIA) 
 
The cellular immune aggression was 
evaluated measuring insulin secretion from 
dispersed rat islet cells co-cultured with MS. 
Diab.MS  and ctr. MS were obtained at days 
4, 6, 9, 12 and 16 after the first injection and 
were cultured 22 hs in RPMI 1640 with or 
without L-NMMA 0,5 mM and washed twice 
with sterile saline solution. Viable MS (90-
95% viability) were used to determine CIA.  
 
Isolation of Dispersed Rat Islet Cells 
 
To obtain islet cells suspensions, freshly 
isolated  rat islets (from collagenase 
treatment) were subjected to EDTA and 
trypsin (Sigma, St. Louis, Mo., USA) (Ono, 
1977). The cells were suspended in basal 
Minimal Essential Medium with Eagle salts 
supplemented with 10% (v/v) fetal calf 
serum, 2 mmol/l glutamine, 1 mmol/l 
sodium piruvate, 0.814 mg/l non-essential 
amino acids (Gibco, UK), 100 U/ml penicillin 
and 100 µg/ml streptomycin. Cell viability 
was estimated by the Trypan  blue exclusion 
test (Phillips, 1973) and only cell 
suspensions having at least 90% viable cells 
were employed. 
 
Islet Cell Stimulation 
 
The islet cell suspension was placed in 96-
well Falcon microtest plates (Becton 
Dickinson,  USA) at 5x103 cells/100 µl per 
well, with addition of 4x105 MS from either 
control or diabetic mice (in 100 µl), or basal 
medium (100 µl) and incubated for 18 h. Ten 
wells were used for each determination. At 
the end of this period, wells were carefully 
washed and the supernatant collected to 
asses prestimulatory insulin release. The 
medium was replaced by 200 µl basal 
medium (glucose 5.5 mmol/l) or 200 µl 
stimulatory medium (glucose 16.5 mmol/l 
plus theophylline 5.5 mmol/l). Five wells 
were used for each basal or stimulatory 
medium. MS remained with cells during both 
basal and stimulatory periods. Supernatants 
were withdrawn after 5 min and rapidly 
frozen for insulin determinations. Islet cells 
function was expressed as the insulin 
secretion (µU/5000 cells) during 5-min 
incubation period in the presence of basal or 
stimulatory medium (Boitard et al., 1982; 
Karabatas et al., 1996 and 2000). Results of 
cellular immune aggression test  were 
reproducible with a 3.89% inter-assay and 
4.20% intra-assay coefficient of variation 
(CV), both for ctr.MS or diab.MS. 
 
Analytical Methods 
 
Serum glucose levels from non fasted mice 
were determined using Glicemia Enzimatica 
Kit (Wiener Lab, Buenos Aires, Argentina). 
Insulin was determined in samples from 
perifusion and in supernatants from islet 
cells-MS cultures by the method of Herbert 
et al. [33]. Pork monoiodine 125I-insulin was 
obtained from CENEXA, Facultad de 
Medicina, Universidad Nacional de La Plata, 
Argentina. Rat standard insulin was obtained 
from Novo Research Laboratories 
(Denmark). Guinea pig anti-porcine insulin 
antiserum was sufficiently "non-specific" as 
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to allow pork labeled insulin to be displaced 
by mouse and rat insulin. Insulin assay 
sensitivity was 0.5 µU/ml; intra-assay CV 
was 8.7%, 6.2% and 5.1% for 1-5, 5-10 and 
10-50 µU insulin/ml determination ranges 
respectively; inter-assay CV were 6.6%, 5.0% 
and 5.2% for the given ranges. 
 
Statistical Analysis 
 
Results were expressed as mean ± SEM. 
Statistical significance was determined by 
ANOVA for plasma glucose levels, insulin 
secretion and nitrite concentration. When 
significance was found, Scheffe's post hoc 
comparisons were made; p less than 0.05 
was accepted as statistically significant.  
To evaluate insulin secretion from perifused 
pancreatic islets we integrated the areas 
under stimulated-insulin secretion curves: 
first secretory peak was integrated between 
min 3 to 7; and the second peak between 
min 9 to 40 of perifusion.  
 
The experimental design and different 
procedures  were schematized  in Figure 1
 
 
Figure 1: Schematic representation of the experimental design. Briefly, pancreas or 
spleens from mld-SZ or control mice were obtained at 4, 6, 9, 12 and 16 days after the 
first injection. Isolated pancreatic islets were perifused to evaluate glucose-stimulated 
insulin secretion. MS were cultured with or without L-NMMA, washed and transferred to 
syngeneic mice or co-cultured with islet cells. Insulin secretion was evaluated in 
recipient mice by islet perifusions or in co-culture supernatants. 
Also, NO° production was measured in islets and MS after 22 hour culture. 
 
Results 
Mice injected with mld-SZ show a 
significant and progressive increase in  
serum glucose levels from day 9 to day 16 
after the first injection of the diabetogenic 
drug (Table 1).  
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Table 1: Non-Fasted Serum Glucose (Mg/Dl) from Control or Mld-SZ Treated Mice. 
 
Days after 
 1st Injection 
 
4 days 
 
6 days 
 
9 days 
 
12 days 
 
16 days 
 
Control Mice 
 
169±4 
n=23 
 
174±4 
n=21 
 
169±5 
n=19 
 
163±4 
n=20 
 
170±3 
n=21 
 
Mld-SZ Mice 
 
172±3 
n=26 
 
167±2 
n=23 
 
338±14ab 
n=26 
 
367±19ab 
n=20 
 
440±25abc 
n=22 
a: p<0.01 vs control mice;  
b: p<0.01 vs mld-SZ mice from days 4 and 6;  
c: p<0.05 vs mld-SZ mice at days 9 and 12. 
 
Basal insulin secretion levels from 
perifused pancreatic islets are not 
significantly different between control and 
mld-SZ mice at all intervals (controls: 0.23 
± 0.02, 16 days after mld-SZ: 0.24 ± 0.01 
μU/min/islet; n=4, p: N.S.). 
Figure 2 shows the waveforms of glucose-
stimulated insulin secretion from perifused 
islets (upper panel) and the areas under 
first and second phases of glucose-induced 
insulin secretion (lower panel). Control 
mice present a biphasic pattern with a first 
phase lasting from minute 3 to minute 7,  
 
and the second phase lasting from minute 
10 to 40. Afterwards, when perifusion 
buffer contains 3.3mM glucose, insulin 
secretion returns to basal levels (min 50). 
Mld-SZ mice present normal secretory 
patterns at days 4 and 6 and significant 
reductions in the first phase of glucose-
stimulated insulin secretion at days 9, 12 
and 16 compared with control mice. Values 
obtained at days 12 and 16 are lower than 
those from day 9. The second phase of 
glucose-stimulated insulin secretion is 
significantly decreased in mld-SZ mice at 
days 12 and 16.
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Figure 2: Upper panel: Glucose-stimulated insulin secretion patterns in perifused islets of 
Langerhans from C57BL/6J mice injected with mld-SZ  or citrate buffer. Isolated islets were 
obtained at days 4  ──■── ,   6 ──▲──, 9 ──n──, 12 ──□── and 16 ──O── after the =irst 
injection  of  mld-SZ, or at 12  days after citrate injection ---◊---. Lower panel: Areas under 
first or second phases of glucose induced insulin secretion from control or mld-SZ injected 
mice.a- p<0.01 versus control mice; b- p<0.01 versus mld-SZ mice at days 4 and 6; c- p<0.01 
vs mld-SZ mice at day 9. At least 5 perifusions were analyzed for each group. Pancreata from 
2 mice were pooled when islets were obtained at days 9, 12 or 16 from mld-SZ mice. Each 
pool was consider as n=1. Each  pancreas of a single mouse was digested when islets were 
isolated from control or mld-SZ mice at days 4 or 6. 
 
Cultured islets of Langerhans, isolated from 
mld-SZ mice, show a significant increase in 
nitric oxide production, at all time 
intervals, when compared with control 
mice. The highest value is obtained when 
islets are isolated at day 6 after the first 
injection of the diabetogenic drug (Figure 
3, upper panel). In agreement with these 
findings, cultured diab.MS also show 
increments in nitric oxide production, 
reaching the maximum level at day 6 
(Figure 3, lower panel). In another set of 
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experiments ctr.MS and diab.MS were 
isolated at 6 or 16 days after the first 
injection and cultured 22 hours with or 
without 0.5 mM L-NMMA to evaluate nitric 
oxide production in supernatants. Results 
show that L-NMMA decreases the 
production of nitric oxide in diab.MS to 
control values while it has no effect on ctr. 
MS (Figure 4). 
  
 
 
Figure 3: Nitrite in supernatants from islet (upper panel) or mononuclear splenocytes 
(MS) (lower panel) cultures. Islets of Langerhans and MS were isolated from citrate 
injected (white bars) or mld-SZ mice (dotted bars) at 4, 6, 9, 12 and 16 days after the first 
injection, as indicated. Experiments with MS were performed in duplicate. * p<0.01 vs. 
controls; # p<0.01 vs mld-SZ from day 6; n=5 to 9 in each group. 
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Figure 4: Nitrite in supernatants from MS cultures. MS were isolated from citrate injected 
(ctr. MS) or mld-SZ mice (diab.MS) at days 6 and 16 after the first injection and 
precultured with (dotted bars) or without (white bars) LNMMA 0.5 mM. *p<0.01 vs ctr. 
MS without LNMMA; #p<0.01 vs. diab.MS without LNMMA; n=4 or 5. Each experiment was 
performed in duplicate. 
 
Diab.MS  impair beta cell function when 
transferred to normal syngeneic mice, 
since perifused freshly isolated islets from 
recipient animals show a significant 
reduction in first-phase of glucose-
stimulated insulin secretion. However, 
when diab.MS were precultured with L-
NMMA before being transferred, we 
observe changes in this deleterious effect 
since first phases of insulin secretion are:  
a) normal in mice transferred with L-
NMMA-treated diab.MS obtained at days 4 
and b) partially impaired when these MS 
are isolated at days 6 and 9.  
 
On the other hand, preculture with L-
NMMA has no effect when diab.MS were 
obtained at days 12 or 16, since insulin 
secretion show similar reductions 
(comparing to recipients of diab.MS  
without L-NMMA). (Table 2). 
 
Table 2: First phase of glucose-induced insulin secretion (μU. 5 min-1. Islet-1) in perifused 
pancreatic islets from mice transferred with mononuclear spleen cells (MS). MS were 
obtained from syngeneic donors at day 4, 6, 9, 12 and 16 after injections with mld-SZ or 
buffer.
 
 Mice Transferred with Ctr.MS  Mice Transferred with Diab.MS  
MS Precultured 
without LNMMA 
MS Precultured 
with LNMMA 
MS Precultured 
without LNMMA 
MS Precultured 
with LNMMA 
4 days 7.50±0.55 
n=4 
8.52±0.36 
n=4 
4.99±0.11b 
n=8 
7.52±0.30ac 
n=8 
6 days 7.97±0.16 
n=4 
8.06±0.21 
n=4 
4.97±0.10b 
n=7 
6.66±0.28abc 
n=7 
9 days 8.32±0.31 
n=5 
8.20±0.40 
n=4 
5.02±0.16b 
n=4 
6.99±0.30abc 
n=6 
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Mice Transferred with Ctr.MS Mice Transferred with Diab.MS 
MS Precultured 
without LNMMA 
MS Precultured 
with LNMMA 
MS Precultured 
without LNMMA 
MS Precultured 
with LNMMA 
12 days 8.23±0.37 
n=4 
7.56±0.24 
n=4 
4.74±0.24b 
n=4 
5.12±0.25b 
n=5 
16 days 7.92±0.17 
n=4 
8.00±0.25 
n=4 
5.00±0.11b 
n=4 
5.72±0.43b 
n=6 
a: p<0.01 vs recipients of diab.MS without LNMMA; 
b: p<0.01 vs recipients of ctr.MS precultured on the same conditions;  
c: p<0.01 vs recipients of diab.MS obtained at days 12 and 16 and pre-cultured with LNMMA.  
 
 
Each perifusion corresponded  to islets 
isolated from a a single transferred  mouse. 
 
In order to investigate the in vitro cellular 
immune aggression we co-cultured 
dispersed rat islet cells with ctr.MS or 
diab.MS, and measured insulin secretion in 
the culture medium. No significant 
differences were found  in the pre-
stimulatory period or in basal condition 
(data not shown). Under stimulatory 
condition, insulin is significantly reduced  
when islet cells are co-cultured with 
diab.MS (obtained at all time intervals).  
However when diab.MS, obtained at days 4 
to 12, were precultured with L-NMMA, they 
exert a lower functional immune 
aggression against  islet cells, since insulin 
levels in the culture medium are 
significantly higher.  At later stages (day 
16) L-NMMA had no preventive effect on 
diab.MS since they are capable to impair 
insulin secretion to similar levels than 
diab.MS without LNMMA (Table 3).
 
Table 3: Cellular immune aggression evaluated as stimulated-insulin secretion (μU. 5 
min-1. 5000 cells-1) in dispersed islet cells co-cultured with mononuclear spleen cells 
(MS). MS were obtained  at day 4, 6, 9, 12 and 16 from mice injected with mld-SZ or 
buffer.
 
 Islet Cells Co-Cultured with Ctr.MS. Islet Cells Co-Cultured with Diab.MS. 
Days 
MS Precultured 
without LNMMA 
MS Precultured 
with LNMMA 
MS Precultured 
without LNMMA 
MS Precultured 
with LNMMA 
4 days 29.06±0.26 
n=4 
29.09±0.66 
n=4 
17.70±1.25b 
n=5 
26.32±0.73abc 
n=5 
6 days 29.00±0.41 
n=4 
29.19±0.31 
n=4 
19.52±0.93b 
n=5 
25.15±0.69abc 
n=5 
9 days 29.78±0.57 
n=5 
30.26±0.29 
n=5 
15.33±0.88b 
n=5 
21.52±0.40ab 
n=5 
12 days 29.25±0.39 
n=4 
28.76±0.27 
n=4 
17.64±0.47b 
n=4 
22.74±0.63ab 
n=4 
16 days 29.11±0.70 
n=4 
28.94±0.16 
n=4 
14.02±0.43b 
n=5 
14.64±0.58bd 
n=5 
a: p<0.01 vs  islet cells plus diab.MS without LNMMA;  
b: p<0.05 vs  islet cells plus ctr.MS precultured on the same conditions;  
c: p<0.01 vs  islet cells plus diab.MS obtained at days 9, 12 and 16 and precultured with 
LNMMA;  
d: p<0.01 vs islet cells plus diab.MS obtained at days 9 and 12 and precultured with LNMMA. 
Five wells were used for each determination. 
 
Discussion 
A variety of cellular components are 
involved in the development of type 1 
diabetes: both CD4+ and CD8+ T cells, 
monocytes, macrophages and NK cells. 
Also, proinflammatory cytokines play 
essential roles in the pathogenesis of the 
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disease (Lehuen et al., 2010; Padgett et al., 
2013) . 
 
Mice injected with mld-SZ develop 
autoimmune diabetes with the appearance 
of progressive hyperglycemia. Mld-SZ 
affects beta cells eliciting a non-specific 
islet inflammation involving toxic 
mediators as free radicals and cytokines 
followed by immune destruction and 
insulitis. In this model, a  variety of 
procedures demonstrated the role of 
immune cells in beta cell damage. Herold et 
al., (1987) showed that administration of 
anti-L3T4 or anti-Lyt-2 monoclonal 
antibodies to mld-SZ mice promoted a 
reduction in hyperglycemia and in splenic 
T-lymphocytes subsets, and a prevention of 
insulitis. Also, athymic mice did not 
develop insulitis or hyperglycemia after 
adminitration of mld-SZ, but when 
immunity was restored by thymus grafting 
insulitis and hyperglycemia became 
evident. This highlight the role of T cells in 
the development of the disease (Paik et al., 
1980; Nakamura et al., 1984). In addition, it 
has been proposed that the balance 
between subsets of T cells (pro or anti 
inflammatory) is important to prevent type 
1 diabetes. Yaochite et al., (2013) 
demonstrated that mice lacking IL-17 
receptor showed an impairment  in mld-SZ 
diabetic course with reduced insulitis and 
beta cell preservation.  
 
Earlier events that preceded the onset of 
hyperglycemia had been described in mld-
SZ mice: a decrease of GLUT2 protein and 
mRNA expression in pancreatic islets, 
increases in the percentage of islet 
apoptotic cells and incipient insulitis at day 
6 after the first streptozotocin injection. 
The free radical nitric oxide (NO°), 
generated by inducible nitric oxide 
synthase (iNOS) has been implicated in 
beta cell destruction leading to type 1  
diabetes since iNOS is mostly not 
expressed under normal conditions but can 
be induced by cytokines to produce large 
amounts of NO°, that often function as a 
cytotoxic molecule for beta cells (O´Brien et 
al., 1996; Wang et al., 1998; Rydgren et al., 
2002; Karabatas et al., 2005; Mabley et al., 
2004 and 2008; Lenzen, 2008; Cernea et al., 
2008; Eizirik et al., 2009; Yasuda et al., 
2009; Lehuen et al., 2010).  In agreement 
with these previous findings (2005),  we 
show here that hyperglycemia is present in 
mld-SZ-treated mice from day 9 after the 
first injection. Moreover, perifused 
pancreatic islets show a progressive 
reduction in the first phase of glucose-
induced insulin secretion while the second 
secretory peak significantly diminishes 
from day 12.  
 
We have also found that increments in NO° 
production, both in cultured islets and MS 
from mld-SZ, appear as early as day 4 after 
the first injection of the diabetogenic drug, 
reaching its highest level at day 6. This 
increased iNOS   activity may constitute an 
important factor in the cascade of events 
leading to beta cells dysfunction and 
culminating in mld-SZ-induced diabetes. 
Flodstrom et al., (1999) and Per-Ola et al., 
(2000) reported that iNOS knockout mice 
treated with mld-SZ show: no changes in 
islet blood flow, a markely decrease in 
insulitis and a reduced sensitivity to 
develop overt diabetes. These findings 
have raised interest in the question of 
whether inhibitors of iNOS could be used to 
prevent the development of Type 1 
diabetes.  
 
A variety of procedures and therapies that 
delete, suppress, or modulate functions of 
the immune and inflammatory system can 
block the response against islet beta cells 
(Stosic-Grijicic et al., 2001; Rydgren et al., 
2002; Yang et al., 2003; Mabley et al., 2004 
and 2008 and Karatug et al., 2013).  In a 
previous work we showed that mld-SZ 
mice injected ip with L-NMMA had 
normoglycemia, preserved first and second 
glucose-induced insulin secretion and a 
diminished anti-beta cell immune 
aggression (Karabatas et al., 1996). It has 
been reported that the use of an iNOS  
inhibitor plus an oxygen species scavenger 
leads to decreases in hyperglycemia and 
incidence of diabetes, a higher pancreatic 
insulin content and absence of pancreatic 
oxidative stress (Mabley et al., 2004). Also, 
mld-SZ mice treated with micophenolato 
mofetil reduced local production of IFN-
gamma as well as IL-12 and NO° 
production by spleen and peritoneal cells 
in mld-SZ mice (Maksimovic-Ivanic et al., 
2002). Moreover, Stocic-Grijicic et al., 
(2001) and Mabley et al., (2008) showed, in 
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“in vivo” studies, a delay or prevention of 
the outbreak of disease after treatment 
with NOS blockers. These findings raised 
the question of whether inhibitors of iNOS 
could be used in vivo to prevent the 
development of type 1 diabetes. However, a 
high selectivity for iNOS seems important 
to prevent side effects that might arise 
from inhibiting the other isoforms. Also, a 
drug with a high selectivity for iNOS can 
inhibit enzyme molecules from cells not 
implicated in beta cell damage.  
 
Diabetes transfer from mouse to mouse 
constitutes an experimental model in 
which insulin secretion impairment was 
induced in healthy naïve recipient mice by 
MS from mld-SZ diabetic donors and it 
appears to be a useful system to study 
mechanisms involved in the onset and 
modulation of autoimmune pancreatic 
aggression (Enghofer et al., 1998; 
Karabatas et al., 2000 and 2005 and 
Pastorale et al., 2002).  
 
Paik et al., (1980) showed that splenocytes 
from mld-SZ +/nu mice induced transient 
glucose intolerance in nu/nu recipients and 
this effect was eliminated when 
splenocytes were depleted of T cells. In 
addition, Arata et al., (1994) showed that 
diab.MS induced abnormal glucose 
tolerance and impaired insulin secretion in 
healthy syngeneic recipients; when diab.MS 
were labeled with Na251CrO4, they showed a 
specific homing towards the pancreas of 
recipient mice indicating an early event in 
the immune aggression. Also, peripheral 
blood mononuclear cells from newly 
diagnosed type 1 diabetic patients migrate 
to the pancreas of athymic mice showing 
again a specific trapping  (Arata et al., 
1995). Moreover, Enghofer et al., (1998) 
showed that transfer of lymphocytes from 
spleens of mld-SZ mice, stained with 
acridine red,  resulted in increased 
lymphocyte rolling and endothelial 
adhesion only in islets of recipient mice 
pretreated with a single subdiabetogenic 
dose of streptozotocin. It has been 
suggested that the pool of transferred 
splenic lymphocytes from mld-SZ mice 
contain immunologically-activated islet-
specific cells that trigger the immune 
aggression in this diabetic model.  
  
Here and in previous studies (2005) we 
show that diab.MS obtained at day 4 were 
able to impair glucose-induced insulin 
secretion when transferred to syngeneic 
animals. In addition we have reported 
(2000) that mice transferred three times 
with diab.MS  showed hyperglycemia and 
diminished first peaks  of glucose and 
arginine-induced insulin secretion.  These 
findings indicate that the capacity of 
diab.MS to impair beta-cell function can be 
modulated. 
 
When diab.MS, obtained at days 6 and 16, 
were pre-cultured with 0.5 mM L-NMMA, 
NO° production diminish to control values. 
Is not clear why L-NMMA is unable to 
suppress NO° production from ctr.MS. We 
can speculate that the concentration of L-
NMMA used in the culture was not high 
enough to completely inhibit NO° 
synthesis.  
 
When we pre-cultured diab.MS with L-
NMMA and then transferred them to 
syngeneic mice, we found different 
patterns of response: when MS  were 
obtained at day 4 they lost the  capacity to 
impair glucose-induced insulin secretion in 
recipient mice; when diab.MS were 
obtained at days 6 and 9 this impairment 
was partial and, at day 16 completely 
manifested. We have not tested if L-NMMA-
treated diab.MS lose the inhibition in NO° 
production if cultured again without L-
NMMA. However, we think that the 
inhibition persist since mice transferred 
with diab.MS (pre-cultured with L-NMMA) 
and killed 15 days later showed a reduced 
impairment in insulin secretion. 
 
The capacity of diab.MS to reduce 
stimulated  insulin secretion can  also be 
studied by means of co-culturing them with 
dispersed rat or mouse islet cells (in vitro 
model) as an evaluation of the cellular 
immune aggression (CIA). One of the 
features of the CIA test is the absence of 
conventional major histocompatibility 
complex restriction, since previous studies 
have shown that peripheral blood 
mononuclear cells from newly diagnosed 
type 1 diabetic patients were able to induce 
CIA in rat and murine pancreatic beta cells. 
Also, MS from mld-SZ mice were found to 
produce CIA on dispersed rat islet cells 
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(Boitard et al., 1982; Arata et al., 1995; 
Karabatas et al., 1996).  In this study, we 
used rat islets because they are more easily 
isolated and hand-picked than mouse 
islets.  
 
CIA seems to be specific for pancreatic beta 
cells, because no cytotoxicity is observed 
against fibroblasts, and secretion of 
glucagon and somatostatin remains 
unaffected (Boitard et al., 1982; Arata et al., 
1994). In this study, diab.MS present CIA at 
an early stage (such as day 4 after mld-SZ) 
concomitantly with their increment in NO° 
production. These facts occur before 
hyperglycemia and reduced insulin 
secretion appear in donor mice.  
 
Diab.MS pre-cultured with L-NMMA also 
exerted a reduced CIA since dispersed islet 
cells secreted higher levels of insulin 
secretion. However, the preventive effect of 
L-NMMA on CIA is not observed at day 16. 
It is possible that at later stages diab. MS 
affect beta cells by means of other 
inflammatory agents in addition to free 
radicals (Cernea et al., 2008; Lehuen et al., 
2010; Buschard K, 2011).  
Conclusions 
The in vitro  inhibition of NO° production 
causes a reduction in the capacity of 
diab.MS to impair insulin secretion in beta 
cells. This effect occurs both when MS are 
co-cultured with dispersed islet cells (CIA) 
or transferred to syngeneic recipient mice. 
However, L-NMMA is not effective when 
MS are isolated from donor mice at later 
stages of the development of diabetes. 
These results suggest that modification of 
the aggressive capacity of diab.MS, avoid, at 
least in part, beta cell damage and 
destruction.  
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